Literature DB >> 23439880

Soluble ST2 as a Diagnostic and Prognostic Marker for Acute Heart Failure Syndromes.

Queen Henry-Okafor1, Sean P Collins, Cathy A Jenkins, Karen F Miller, David J Maron, Allen J Naftilan, Neal Weintraub, Gregory J Fermann, John McPherson, Santosh Menon, Douglas B Sawyer, Alan B Storrow.   

Abstract

OBJECTIVES: We investigated the association of sST2 with diagnostic and prognostic outcomes and assessed whether it aids B-natriuretic peptide (BNP) in diagnosing and predicting outcomes in emergency department (ED) patients with suspected AHFS.
METHODS: We recruited patients who presented to the ED of 3 tertiary hospitals with signs or symptoms of AHFS and met modified Framingham criteria for AHFS. Outcome measures were a final diagnosis of AHFS and 5-and 30-day adverse events.
RESULTS: In the 295 subjects with sST2 available, the median sST2 was 0.20 ng/ml (IQR=0.10, 0.34). Although unadjusted analyses indicated sST2 was significantly associated with the diagnosis of AHFS (p=0.02), this was not so in the adjusted analysis (p=0.33). Moderately low diagnostic utility was noted with an AUC of 0.62 (95% CI=0.56, 0.69). Similar sST2 test characteristics were seen when BNP was restricted between 100 and 500 pg/ml. While sST2 was associated with AHFS readmission at 30-days (p=0.04), in the adjusted analyses it was not associated with adverse events.
CONCLUSION: In patients with signs or symptoms of AHFS, unadjusted analyses indicated that sST2 was significantly associated with the diagnosis of AHFS and with 30-day AHFS recidivism. However, the associations did not carry over to adjusted analyses, and sST2 did not add significant information with regard to explaining the diagnostic and prognostic variability of BNP.

Entities:  

Keywords:  Acute heart failure; Diagnosis; Prognosis; Soluble ST2

Year:  2012        PMID: 23439880      PMCID: PMC3578210          DOI: 10.2174/1875318301205010001

Source DB:  PubMed          Journal:  Open Biomark J


  23 in total

1.  Acute heart failure syndromes: current state and framework for future research.

Authors:  Mihai Gheorghiade; Faiez Zannad; George Sopko; Liviu Klein; Ileana L Piña; Marvin A Konstam; Barry M Massie; Edmond Roland; Shari Targum; Sean P Collins; Gerasimos Filippatos; Luigi Tavazzi
Journal:  Circulation       Date:  2005-12-20       Impact factor: 29.690

2.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

Authors:  E R DeLong; D M DeLong; D L Clarke-Pearson
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

Review 3.  Novel markers for heart failure diagnosis and prognosis.

Authors:  Douglas S Lee; Ramachandran S Vasan
Journal:  Curr Opin Cardiol       Date:  2005-05       Impact factor: 2.161

4.  Construction of ELISA system to quantify human ST2 protein in sera of patients.

Authors:  K Kuroiwa; H Li; K Tago; H Iwahana; K Yanagisawa; N Komatsu; K Oshikawa; Y Sugiyama; T Arai; S I Tominaga
Journal:  Hybridoma       Date:  2000-04

5.  Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure.

Authors:  Saskia Boisot; Jennifer Beede; Susan Isakson; Albert Chiu; Paul Clopton; James Januzzi; Alan S Maisel; Robert L Fitzgerald
Journal:  J Card Fail       Date:  2008-07-26       Impact factor: 5.712

6.  The diagnostic usefulness of the history of the patient with dyspnea.

Authors:  B P Schmitt; M S Kushner; S L Wiener
Journal:  J Gen Intern Med       Date:  1986 Nov-Dec       Impact factor: 5.128

7.  Identification of serum soluble ST2 receptor as a novel heart failure biomarker.

Authors:  Ellen O Weinberg; Masahisa Shimpo; Shelley Hurwitz; Shin-ichi Tominaga; Jean-Lucien Rouleau; Richard T Lee
Journal:  Circulation       Date:  2003-02-11       Impact factor: 29.690

8.  Identification of the primary growth response gene, ST2/T1, as a gene whose expression is differentially regulated by different protein kinase C isozymes.

Authors:  A Kieser; J Goodnight; W Kölch; H Mischak; J F Mushinski
Journal:  FEBS Lett       Date:  1995-09-25       Impact factor: 4.124

Review 9.  State of the art: using natriuretic peptide levels in clinical practice.

Authors:  Alan Maisel; Christian Mueller; Kirkwood Adams; Stefan D Anker; Nadia Aspromonte; John G F Cleland; Alain Cohen-Solal; Ulf Dahlstrom; Anthony DeMaria; Salvatore Di Somma; Gerasimos S Filippatos; Gregg C Fonarow; Patrick Jourdain; Michel Komajda; Peter P Liu; Theresa McDonagh; Kenneth McDonald; Alexandre Mebazaa; Markku S Nieminen; W Frank Peacock; Marco Tubaro; Roberto Valle; Marc Vanderhyden; Clyde W Yancy; Faiez Zannad; Eugene Braunwald
Journal:  Eur J Heart Fail       Date:  2008-08-29       Impact factor: 15.534

10.  Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure.

Authors:  Thomas Mueller; Benjamin Dieplinger; Alfons Gegenhuber; Werner Poelz; Richard Pacher; Meinhard Haltmayer
Journal:  Clin Chem       Date:  2008-04       Impact factor: 8.327

View more
  6 in total

1.  Biomarkers associated with 30-day readmission and mortality after pediatric congenital heart surgery.

Authors:  Devin M Parker; Allen D Everett; Meagan E Stabler; Luca Vricella; Marshall L Jacobs; Jeffrey P Jacobs; Heather Thiessen-Philbrook; Chirag R Parikh; Jeremiah R Brown
Journal:  J Card Surg       Date:  2019-04-03       Impact factor: 1.620

2.  Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction.

Authors:  Fernando Friões; Patrícia Lourenço; Olga Laszczynska; Pedro-Bernardo Almeida; João-Tiago Guimarães; James L Januzzi; Ana Azevedo; Paulo Bettencourt
Journal:  Clin Res Cardiol       Date:  2015-01-14       Impact factor: 5.460

Review 3.  Soluble ST2: a valuable prognostic marker in heart failure.

Authors:  Sugeevan Savarimuthu; Pavan Goel; Amer Harky
Journal:  Heart Fail Rev       Date:  2022-06-27       Impact factor: 4.654

4.  Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure.

Authors:  Dong-Hui Huang; Hao Sun; Jing-Pu Shi
Journal:  Chin Med J (Engl)       Date:  2016-03-05       Impact factor: 2.628

5.  Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis.

Authors:  Yujiao Shi; Jiangang Liu; Chunqiu Liu; Xiong Shuang; Chenguang Yang; Wenbo Qiao; Guoju Dong
Journal:  Front Cardiovasc Med       Date:  2022-09-20

6.  Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction.

Authors:  Yameng Cui; Xin Qi; Anan Huang; Jiao Li; Wenguang Hou; Keqiang Liu
Journal:  Med Sci Monit       Date:  2018-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.